Onconex Head and Neck Cancer (Somatic)

The Onconex Head and Neck Cancer (Somatic) test is a comprehensive Next Generation Sequencing (NGS) assay targeting 125 genes associated with head and neck cancers, providing detailed genetic insights to guide targeted therapy and improve patient outcomes.

The Onconex Head and Neck Cancer (Somatic) test offers insights into the molecular underpinnings of tumor mutation genes, facilitating the identification of novel genetic aberrations and potential therapeutic targets. As targeted therapies become the new standard of care in oncology, the Onconex Head and Neck Cancer (Somatic) test empowers clinicians to optimize patient treatment plans based on the genetic profile of the tumor. NGS technology enables massively parallel sequencing for a large number of genes with accurate reads, making it a cost-effective diagnostic approach.

Head and neck cancer (HNC) is the seventh most common cancer globally, accounting for more than 660,000 new cases and 325,000 deaths annually. Head and neck squamous cell carcinoma (HNSCC) comprises a heterogeneous group of tumors that arise from the squamous epithelium of the oral cavity, oropharynx, larynx, and hypopharynx. More than 90% of tumours in the head and neck are squamous carcinomas.

Complex chromosomal changes and gene copy number alterations are present across the spectrum of HNSCC and are evident in premalignant disease. Tumour Biomarkers can characterise the diversity of the cancer, and perhaps point to gene targets for use in targeted and personalised medicine. 

NGS enables massively parallel sequencing for a large number of genes with accurate reads while being relatively inexpensive.

Clinical Utility: 

• Identify Driver Mutations - mutation in the DNA Sequence that cause cells to become cancers, grow & spread in body.
• Drug profiling for Chemotherapy & Targeted Drugs.
• Predictive genomic biomarker identification to guide the therapeutic process.
• The targeted NGS panel offers wide coverage and in-depth analysis to detect the known and novel variants.
• The multigene approach reduces the time for diagnosis providing a more economical solution.

Panels Covered:

• Comprehensive genomic profiling for 125 cancer genes associated with head and neck cancers.
• Screening for clinically significant genes based on National Comprehensive Cancer Network (NCCN) guidelines.
• Genetic counselling to guide through the report and discuss the available management & treatment options in case of clinical findings.
• Reporting - Pathogenic and Likely Pathogenic Variants are reported following the ACMG recommended guidelines.
• Best in class Bioinformatics pipeline for the most accurate analysis by our experienced Bioinformatics team.

Who Should Get Tested?

• Patients diagnosed with head and neck squamous cell carcinoma (HNSCC) seeking personalized treatment options.
• Individuals with a family history of head and neck cancers.
• Patients with complex chromosomal changes and gene copy number alterations.
• Clinicians looking for comprehensive genomic profiling to inform targeted therapies.

What Does the Report Tell Me?

The Onconex Head and Neck Cancer (Somatic) test report provides detailed insights into the genetic mutations driving head and neck cancers. It identifies driver mutations, informs drug profiling for chemotherapy and targeted drugs, and highlights predictive genomic biomarkers to guide the therapeutic process. The report includes pathogenic and likely pathogenic variants following ACMG guidelines, offering a clear understanding of the molecular underpinnings of the tumor and potential treatment options.

Next Steps Post Getting the Report:

After receiving the Onconex Head and Neck Cancer (Somatic) test report, the following steps are recommended:

• Schedule a genetic counseling session to interpret the results and discuss available management and treatment options.
• Discuss the report with your healthcare provider to tailor the treatment plan based on the genetic profile of the tumor.
• Consider targeted therapies and other personalized treatment options informed by the genomic insights provided in the report.
• Utilize the free genetic counseling offered to navigate the results, explore therapeutic strategies, and make informed decisions about your treatment plan.

Note: Pre-test & post-test genetic counseling can be provided. If interested please send the request to this email id: [email protected]   

Disclaimer: In no event shall the liability of TATA 1MG exceed the amount of actual cost of test charges incurred by the customer as stated on the invoice issued by Tata 1mg.